Business Wire

IPROOV

Share
iProov Face Verification Selected by itsme® to Support Global Expansion

British company iProov has today announced that European digital identity leader, itsme®, has selected iProov’s Genuine Presence Assurance® technology to support its global expansion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419006005/en/

Launched in 2017 by qualified trust service provider, Belgian Mobile ID, itsme® is Belgium's digital identity app. It is currently used by more than 35% of the Belgian population and is relied on by more than 150 companies in the private sector (banks, insurance companies etc) and by the Belgian government. From now, users in the Netherlands will also have access to itsme®’s trusted ID solution and will be able to securely authenticate themselves and onboard to digital services. iProov will verify the faces of new users, whatever their mobile device.

“We needed a technology partner to support our mission to make secure digital identities available to everyone. iProov was the obvious choice. They hold privacy and security in the highest regard and offer the future-proof, cutting-edge technology that will enable us to identify users internationally,” Stephanie De Bruyne, CEO at itsme, said.

Onboarding for an eIDAS level high or qualified signature has to meet very demanding, independently audited and certified international standards. Previously, these could only be met by an in-person meeting or video calling. itsme® avoids these expensive and tedious methods by using iProov’s faster, more convenient, less costly and more secure solution.

iProov’s Genuine Presence Assurance technology enables users to onboard to the itsme® service in a way that is both secure and effortless to use. A user scans their identity document using their mobile device. They then scan their face in a process that takes a few brief seconds. iProov technology ensures that the user is the right person, matching the identity in the document, that they are a real person, and that they are authenticating right now. The iProov process maximizes inclusiveness by eliminating the need for users to follow instructions to move or read out words.

Andrew Bud, Founder and CEO of iProov, said: “We are delighted to be working with itsme®, a true pioneer in the provision of digital identity trust services. I have huge respect for how itsme® has successfully driven the uptake of digital identity in Belgium, so it’s a pleasure and privilege to be partnering on a solution for the Netherlands. This is yet another demonstration that iProov is the technology of choice for Europe’s leading eIDAS providers.”

itsme® enables identification, secure onboarding, authentication on website or app, confirmation of transactions and qualified electronic signatures, all to the highest level of security. itsme® was granted accreditation by the Belgian government as an official form of digital identity in 2018 and on a European level in 2019 (LOA high eIDAS).

About iProov

Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance™ and Genuine Presence Assurance®, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.

About itsme®

Since its launch in 2017, the itsme® app has become the widely accepted simple and secure standard for mobile identification and the protection of privacy in the digital world. itsme® enables the following: identification (creating a new online account and sharing identity details), authentication (secure, personal access to a website or application), confirmation of a transaction (approval of an order or bank payment) and, finally, the legally binding electronic signing of documents (qualified electronic signature with the highest level of security). itsme® was granted accreditation by the Belgian government as an official form of digital identity in January 2018 and on a European level in December 2019 (LOA high eIDAS). The itsme® app is used extensively in the financial sector among others because it complies with PSD2, FATF and GDPR guidelines. It has also been awarded ISO27001 certification.

itsme® was developed by the Belgian Mobile ID consortium, which combines the seven Belgian market leaders from the banking and telecommunications sectors: Belfius, BNP Paribas Fortis, CBC/KBC & ING, on the one hand, and Orange Belgium, Proximus and Telenet on the other. itsme® takes the security of the electronic identity card to the world of mobile.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release

The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release

Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on

Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release

Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye